Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

Eli Lilly & Co.’s shares saw the biggest one-day drop since 2008 after CVS Health Corp. announced a plan to drop its ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

Eli Lilly (LLY) stock dips as CVS Health (CVS) limits access to its weight loss drug Zepbound in favor of Novo Nordisk's (NVO ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

Lilly CEO says businesses most affected by CVS move are small employers Stock reaction to CVS decision is 'overblown,' says investor Lilly tops Wall Street view for first quarter profit ...

CVS said it will expand access to blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark.

Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly’s obesity drug Zepbound from its standard commercial formularies starting July 1, 2025. The market overreacted to ...

Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.